Exelixis traded at $21.53 this Wednesday July 6th, decreasing $0.74 or 3.32 percent since the previous trading session. Looking back, over the last four weeks, Exelixis lost 10.58 percent. Over the last 12 months, its price rose by 19.81 percent. Looking ahead, we forecast Exelixis to be priced at 20.99 by the end of this quarter and at 19.33 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,896.00 34.00 0.88% 5.73%
Eisai 6,174.00 7.00 0.11% -41.17%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Agios Pharmaceuticals 25.35 -0.10 -0.39% -55.38%
Akebia Therapeutics 0.46 0.05 12.47% -86.39%
Amgen 245.25 -1.48 -0.60% 0.83%
AstraZeneca 10,978.00 178.00 1.65% 26.80%
Bayer 56.19 0.67 1.21% 10.24%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Bristol-Myers Squibb 76.22 0.26 0.34% 13.52%
Cytokinetics 44.14 0.24 0.55% 123.27%
Esperion Therapeutics 6.69 -0.30 -4.29% -65.25%
Exelixis 21.53 -0.74 -3.32% 19.81%
Genmab 2,415.00 8.00 0.33% -9.82%
Glaxosmithkline 43.11 -0.19 -0.44% 7.13%
Immunogen 5.15 0.25 5.10% -16.94%
Incyte Corp 79.72 0.47 0.59% -2.93%
Ionis Pharmaceuticals 36.81 -1.04 -2.75% -5.52%
Eli Lilly 330.15 2.97 0.91% 40.00%
MacroGenics 3.42 0.11 3.32% -87.76%
Merck & Co 93.13 0.49 0.53% 18.55%
Moderna Inc 159.56 4.02 2.58% -28.09%
Mirati Therapeutics 69.83 -2.13 -2.96% -56.07%
Neurocrine Biosciences 95.20 -3.10 -3.15% -3.05%
Nektar Therapeutics 3.90 -0.03 -0.76% -76.53%
Novartis 81.22 0.31 0.38% -4.41%
Puma Biotechnology 2.78 0.12 4.51% -66.34%
Pfizer 52.75 1.11 2.15% 34.05%
Ultragenyx Pharmaceutical 63.38 -0.42 -0.66% -29.29%
Seattle Genetics 175.13 -1.64 -0.93% 16.96%
Sanofi 50.04 -0.14 -0.28% -2.28%
Xencor 32.44 1.99 6.54% -4.14%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%
US400 2279 -13.85 -0.60% -15.05%

Exelixis
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.